---
title: Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers
nct_id: NCT06135896
overall_status: RECRUITING
phase: PHASE2
sponsor: National Cancer Center, Korea
study_type: INTERVENTIONAL
primary_condition: Unresectable Pancreatic Cancer
countries: South Korea
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT06135896.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06135896"
ct_last_update_post_date: 2025-06-18
last_seen_at: "2026-05-12T06:14:05.285Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers

**Official Title:** An Open-label, Randomized, Multicenter, Phase II Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers

**NCT ID:** [NCT06135896](https://clinicaltrials.gov/study/NCT06135896)

## Key Facts

- **Status:** RECRUITING
- **Phase:** PHASE2
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 98
- **Lead Sponsor:** National Cancer Center, Korea
- **Collaborators:** Seoul National University Hospital
- **Conditions:** Unresectable Pancreatic Cancer, Unresectable Bile Duct Carcinoma, Unresectable Biliary Tract Carcinoma
- **Start Date:** 2024-01-16
- **Completion Date:** 2026-06-30
- **CT.gov Last Update:** 2025-06-18

## Brief Summary

* Clinical trial phase: Phase 2
* Intervention model: Control group
* Group allocation: Randomized controlled trial
* Research perspective: Prospective study
* Participating centers: Multicenter study
* Definition of the intervention period: Based on the RECIST 1.1 guidelines, patients will receive treatment until dropout due to disease progression or unacceptable toxicity related to the trial drug. Patients will be followed up with to assess survival every 2 months until either death or the end of the trial, whichever is first.
* The intervention period is from the date of IRB approval to December 31st, 2025
* The follow-up duration is one year, and the statistical analysis duration is six months
* The total research period is from the date of IRB approval to June 30th, 2026

## Detailed Description

Pancreatic cancer and Bile duct cancer are the 8th and 9th leading causes of all cancer in Korea, have 5-year survival rates of approximately 20%, and unresectable cancers show a poor prognosis of approximately 5%. The first-line treatment recommended for unresectable pancreaticobiliary cancer is chemotherapy. FOLFIRINOX or gemcitabine/nab-paclitaxel combination therapy is recommended for pancreatic cancer, and gemcitabine/cisplatin combination therapy is recommended for bile duct cancer. Recently, anticancer therapy advances have led to an increase in survival for pancreaticobiliary cancer patients, and more than half of patients receive secondary chemotherapy due to disease progression after first-line treatment. Recently, with the introduction of nanoliposomal irinotecan (nal-IRI) and the clinical outcomes of Phase 3 NAPOL-1 trial and the Phase 2b NIFTY trial, nal-IRI/5-FU/LV combination therapy is being used as second-line chemotherapy following gemcitabine treatment. Granulocyte colony-stimulating factors (G-CSFs) (filgrastim, pegfilgrastim, and tripegfilgrastim) can be used for neutropenia prevention and treatment. In particular, pegylated G-CSF can reduce patient discomfort due to its long retention time. In a retrospective study analyzing the use of G-CSF for primary neutropenia prevention in Korea, pancreatic cancer patients who received FOLFIRINOX treatment that exhibited neutropenia and FN were significantly reduced from 55.6% to 31.6% (P = 0.003) and from 18.5% to 1.8% (P = 0.002), respectively. Similarly, in a retrospective study in Japan, preventive pegylated G-CSF treatment reduced the incidence of FN from 23% to 0%, and in a double-blinded, randomized, phase 3 breast cancer clinical trial, pegylated G-CSF treatment significantly reduced the incidence of FN from 68.8% to 1.2%. In a retrospective study of non-small cell lung cancer, another solid cancer, the incidence of FN in the preventive pegylated G-CSF treatment group was 0%, compared to an incidence of 50% in the control group.

However, no studies have evaluated the efficacy of G-CSF in pancreaticobiliary cancer patients receiving nal-IRI/5-FU/LV combination therapy yet. Hence, our objective was to report the effects of pegylated G-CSF on preventing severe neutropenia in patients receiving nal-IRI/5-FU/LV combination chemotherapy for unresectable pancreaticobiliary cancer.

## Eligibility

- **Minimum age:** 19 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Patients aged at least 19 years old, diagnosed with unresectable pancreaticobiliary cancer, and scheduled to receive chemotherapy using nal-IRI/5-FU/LV combination chemotherapy

Exclusion Criteria:

* Patients who refuse to sign the consent form Patients who have previously experienced severe neutropenia during chemotherapy
```

## Arms

- **Treatment Group** (EXPERIMENTAL) — * Premedication: depending on the center (Ondansetron 8 mg +Dextrose 5% 50 mL, MIV, Dexamethason 10 mg IV, and Atropine sulfate 0.25 mg \[0.5 amp\] SC)
* Onivyde 70 mg/m2 + Dextrose 5% 500 mL (bag), and MIV for 90 min
* Leucovorin 400 mg/m2 + Dextrose 5% 500 mL (bag), and MIV for 30 min
* 5-FU (2400 mg/m2) + Dextrose 5% 500 mL (bag) and MIV for 46 h
* Tripegfilgrastim 6 mg SC administered 24 h after completing 5-FU infusion The above chemotherapy will be administered every two weeks
- **Control Group** (NO_INTERVENTION) — * Premedication: depending on center (Ondansetron 8 mg+Dextrose 5% 50 mL, MIV, Dexamethason 10 mg IV, and Atropine sulfate 0.25 mg \[0.5 amp\] SC)
* Onivyde 70 mg/m2 + Dextrose 5% 500 mL (bag), and MIV for 90 min
* Leucovorin 400 mg/m2 + Dextrose 5% 500 mL (bag), and MIV for 30 min
* 5-FU (2400 mg/m2) + Dextrose 5% 500 mL (bag), and MIV for 46 h The following medication will be provided in the event that the patient develops febrile neutropenia after the above chemotherapy
* Tripegfilgrastim 6 mg SC administered 24 h after stopping 5-FU. In the event of neutropenia, chemotherapy will be paused until the patient recovers, and then restarted after recovery.
* The above chemotherapy will be administered every two weeks.

## Interventions

- **Tripegfilgrastim** (DRUG) — Tripegfilgrastim to reduce the risk of severe neutropenia in patients with unresectable pancreaticobiliary cancers

## Primary Outcomes

- **Primary endpoint** _(time frame: through study completion, an average of 1 year)_ — Severe neutropenia incidence

## Secondary Outcomes

- **neutropenia incidence** _(time frame: through study completion, an average of 1 year)_
- **Febrile neutropenia** _(time frame: through study completion, an average of 1 year)_
- **emergency department visits** _(time frame: through study completion, an average of 1 year)_
- **Overall survival** _(time frame: through study completion, an average of 1 year)_
- **Progression-free survival** _(time frame: through study completion, an average of 1 year)_
- **biomarkers** _(time frame: through study completion, an average of 1 year)_

## Locations (1)

- NATIONAL CANCER CENTER 323, Ilsan-ro, Ilsandong-gu,, Goyang-si, Gyeonggi-do, South Korea — _RECRUITING_

## Recent Field Changes (last 30 days)

- `outcomes.primary` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.national cancer center 323, ilsan-ro, ilsandong-gu,|goyang-si|gyeonggi-do|south korea` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT06135896.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT06135896*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*